How would you know that? Are you privy to insider information that the rest of us are not? Or are you just pulling nonsense out of your arse again? Because according to Redman, the few patients in Phase I that they have data on, the drug showed efficacy and near complete response. The drug is extremely well tolerated with very minimal side effects. Hardly sounds "disappointing" to me.
The trials are going to be highly disappointing when they are announced.
News 
Market Data 
Discover 
AI
